中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

113 records (took 0.021 seconds)

    IMPROVED DETECTION OF GENE EXPRESSION
    3.
    发明申请
    IMPROVED DETECTION OF GENE EXPRESSION 审中-公开
    改进基因表达的检测

    公开(公告)号：WO2010105815A3

    公开(公告)日：2010-11-25

    申请号：PCT/EP2010001674

    申请日：2010-03-17

    Applicant: ONCOMETHYLOME SCIENCES S A ,  OTTO GAETAN ,  BOVIE CATHERINE ,  GLAXOSMITHKLINE BIOLOG SA

    Inventor： OTTO GAETAN ,  BOVIE CATHERINE

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156

    Abstract: An oligonucleotide, primer or probe comprises the nucleotide sequence of any of SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 61, 62 or 63. The oligonucleotide, primer or probe is useful for the detection of the methylation status of a gene. The oligonucleotides find application in the diagnosis and treatment of cancer.

    Abstract translation: 寡核苷酸，引物或探针包含SEQ ID NO： 1，2，3，4，5，6，7，8，9，10，11，12，13，14，15，16，17，18，19，20，21，22，23，24，25 ，26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,44,61,62或63.寡核苷酸，引物或探针是 可用于检测基因的甲基化状态。 寡核苷酸可用于诊断和治疗癌症。

    VACCINE
    4.
    发明申请
    VACCINE 审中-公开
    疫苗

    公开(公告)号：WO2009071613A2

    公开(公告)日：2009-06-11

    申请号：PCT/EP2008066762

    申请日：2008-12-04

    Applicant: GLAXOSMITHKLINE BIOLOG SA ,  COHEN JOSEPH D ,  MARCHAND MARTINE

    Inventor： COHEN JOSEPH D ,  MARCHAND MARTINE

    IPC: A61K39/00

    CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55572 ,  A61K2039/55577 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10343

    Abstract: The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and use of the viral vector in the treatment/prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect the invention employs a synthetic C7 viral vector. The C7 viral vector according to the invention may be co-administered or co-formulated with a malaria antigen such as RTS,S optionally in the presence of an adjuvant for example comprising 3D-MPL and/or a saponin such as QS21.

    Abstract translation: 本发明涉及编码包含来自恶性疟原虫或其片段的CS蛋白的蛋白的复制缺陷型猿猴腺病毒载体C7，例如如Seq ID No：1或Seq ID No：3所示。本发明还涉及 制备所述病毒载体和使用病毒载体治疗/预防疟疾感染。 还描述了包含所述病毒载体的组合物，疫苗和试剂盒。 一方面，本发明使用合成的C7病毒载体。 根据本发明的C7病毒载体可以任选地在例如包含3D-MPL和/或皂苷例如QS21的佐剂存在下共同施用或与疟疾抗原例如RTS，S共配制。

    PROCESS FOR MANUFACTURING VACCINES
    8.
    发明申请
    PROCESS FOR MANUFACTURING VACCINES 审中-公开
    制造疫苗的方法

    公开(公告)号：WO2008081014A2

    公开(公告)日：2008-07-10

    申请号：PCT/EP2008050011

    申请日：2008-01-02

    Applicant: GLAXOSMITHKLINE BIOLOG SA ,  BIEMANS RALPH LEON ,  DUVIVIER PIERRE

    Inventor： BIEMANS RALPH LEON ,  DUVIVIER PIERRE

    IPC: A61K39/00

    CPC classification number: A61K39/385 ,  A61K47/48261 ,  A61K47/4833 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/627 ,  Y10S424/831 ,  Y10S530/807

    Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide - protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.

    Abstract translation: 本申请公开了一种制备免疫原性组合物的方法，其包含使用碳二亚胺缩合化学法进行糖 - 蛋白质共轭反应的改进方法。 根据所涉及的糖或蛋白质载体的性质，可以通过将反应组分中的一种缓慢加入到反应混合物中来改善缀合物的质量。 此外，缀合物与葡萄球菌抗原混合。 进一步提供包含通过所公开的方法制备的糖 - 蛋白质共轭物的免疫原性组合物。

    VACCINES FOR MALARIA
    9.
    发明申请
    VACCINES FOR MALARIA 审中-公开
    疟疾疫苗

    公开(公告)号：WO2008009650A3

    公开(公告)日：2008-04-10

    申请号：PCT/EP2007057296

    申请日：2007-07-16

    Applicant: GLAXOSMITHKLINE BIOLOG SA ,  US ARMY ,  COHEN JOSEPH D ,  MARCHAND MARTINE ,  OCKENHOUSE CHRISTIAN F ,  YADAVA ANJALI

    Inventor： COHEN JOSEPH D ,  MARCHAND MARTINE ,  OCKENHOUSE CHRISTIAN F ,  YADAVA ANJALI

    IPC: A61K39/015 ,  A61K39/29

    CPC classification number: A61K39/015 ,  A61K2039/6075 ,  C07K14/445 ,  C07K2319/40

    Abstract: The present invention relates to a lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.

    Abstract translation: 本发明涉及脂蛋白颗粒，其制备和纯化方法，其在药物中的用途，特别是在预防疟疾感染中，含有颗粒的组合物/疫苗或针对蛋白质颗粒的抗体，例如单克隆或多克隆抗体和使用 相同的，特别是在治疗。 尤其涉及包含以下单体的免疫原性蛋白质颗粒：a。 包含源自间日疟原虫的CS蛋白的序列和乙型肝炎的S抗原（CSV-S）的融合蛋白，以及b。 包含衍生自恶性疟原虫的CS蛋白和乙型肝炎（RTS）的S抗原的序列的融合蛋白，以及c。 任选地来自乙型肝炎的S抗原。

    PRODER P 1 EXPRESSED IN A PROKARYOTIC CELL
    10.
    发明申请
    PRODER P 1 EXPRESSED IN A PROKARYOTIC CELL 审中-公开
    PRODER P 1在原始细胞中表达

    公开(公告)号：WO2007116089A3

    公开(公告)日：2008-04-10

    申请号：PCT/EP2007053554

    申请日：2007-04-12

    Applicant: GLAXOSMITHKLINE BIOLOG SA ,  JACQUET ALAIN ,  MATTEOTTI CHRISTEL ,  WALGRAFFE DAVID

    Inventor： JACQUET ALAIN ,  MATTEOTTI CHRISTEL ,  WALGRAFFE DAVID

    IPC: C07K14/435 ,  A61K39/35 ,  C12N9/64

    CPC classification number: C07K14/43531

    Abstract: This invention relates to novel methods for producing hypoallergenic recombinant derivatives of ProDer p 1, the precursor form of the major protein allergen from Dermatophagoides pteronyssinus Der p 1, and to the derivatives produced by such methods. The invention further relates to the use of said hypoallergenic recombinant ProDer p 1 derivatives in formulating immunogenic compositions and vaccines effective in the prevention and/ or the reduction of allergic responses to specific allergens. The invention also relates to novel ProDer p 1 protein and nucleic acid sequences.

    Abstract translation: 本发明涉及用于生产由Dermatophagoides pteronyssinus Der p 1制备的主要蛋白质变应原的前体形式的ProDer p1的低变应原性重组衍生物的新方法以及由这些方法产生的衍生物。 本发明还涉及所述低变应原性重组ProDer p1衍生物在配制有效预防和/或减少对特定变应原的过敏反应的免疫原性组合物和疫苗中的用途。 本发明还涉及新型的ProDer p1蛋白和核酸序列。

Patent Agency Ranking